Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Hypertrophy Clear all
Completed No phase listed Observational

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

NCT01873963
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Not listed
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

NCT00001965
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Interventions
Cyclosporine A
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
View directory record Official record
Conditions
Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk

NCT05646056
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Hypertrophic, Left Ventricular Hypertrophy
Interventions
Software
Device
Lead sponsor
Prolaio
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT02413450
View directory record Official record
Conditions
Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593
View directory record Official record
Conditions
Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions
Valsartan 80 mg
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

NCT03043209
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Genetic Disease, Gene Product Sequence Variation
Interventions
Genomic sequencing
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Blood Flow in Heart Muscle

NCT00001631
View directory record Official record
Conditions
Coronary Disease, Healthy, Hypertrophic Cardiomyopathy, Myocardial Ischemia
Interventions
Magnetic resonance imaging
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

NCT05818605
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Moderate Intensity Exercise Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 4 Interventional

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Kansas City, Missouri • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Withdrawn No phase listed Observational

The Genetics of Cardiomyopathy and Heart Failure

NCT00703443
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Mitochondrial Cardiomyopathy, Noncompaction Cardiomyopathy, Restrictive Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 23, 2026, 2:17 PM EDT
Terminated Phase 3 Interventional Results available

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Results available

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve

NCT03225001
View directory record Official record
Conditions
Aortic Stenosis, Cardiomyopathy, Hypertrophic
Interventions
Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
46
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

NCT03767855
View directory record Official record
Conditions
Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions
CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures

NCT00692991
View directory record Official record
Conditions
Myocardial Infarction, Angina, Unstable, Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

NCT05305911
View directory record Official record
Conditions
Heart Attack, Enlarged Heart
Interventions
SGLT-2 inhibitors, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort

NCT00344903
View directory record Official record
Conditions
Atherosclerosis, Congestive Heart Failure, Left Ventricular Hypertrophy, Diabetes Mellitus, Hypertension, Obesity, Metabolic Syndrome X, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years to 70 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 1 Interventional

Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...

NCT00001396
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Paragon Pacemaker
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:17 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement

NCT01198873
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone, Placebo (for Dronedarone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Jul 23, 2026, 2:17 PM EDT